Status of care for end stage kidney disease in countries and regions worldwide:international cross sectional survey by Bello, Aminu K et al.
                          Bello, A. K., Levin, A., Lunney, M., Osman, M. A., Ye, F., Ashuntantang, G.
E., ... Johnson, D. W. (2019). Status of care for end stage kidney disease in
countries and regions worldwide: international cross sectional survey. BMJ,
367, [l5873 ]. https://doi.org/10.1136/bmj.l5873
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmj.l5873
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ at
https://www.bmj.com/content/367/bmj.l5873. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
the bmj | BMJ 2019;367:l5873 | doi: 10.1136/bmj.l5873 1
RESEARCH
Status of care for end stage kidney disease in countries and  
regions worldwide: international cross sectional survey
Aminu K Bello,1 Adeera Levin,2 Meaghan Lunney,3 Mohamed A Osman,4 Feng Ye,1  
Gloria E Ashuntantang,5 Ezequiel Bellorin-Font,6 Mohammed Benghanem Gharbi,7  
Sara N Davison,1 Mohammad Ghnaimat,8 Paul Harden,9 Htay Htay,10 Vivekanand Jha,11,12,13 
Kamyar Kalantar-Zadeh,14,15 Peter G Kerr,16,17 Scott Klarenbach,1 Csaba P Kovesdy,18,19  
Valerie A Luyckx,20,21 Brendon L Neuen,22 Donal O’Donoghue,23,24 Shahrzad Ossareh,25  
Jeffrey Perl,26,27 Harun Ur Rashid,28 Eric Rondeau,29,30 Emily See,31,32 Syed Saad,1 Laura Sola,33 
Irma Tchokhonelidze,34 Vladimir Tesar,35 Kriang Tungsanga,36,37 Rumeyza Turan Kazancioglu,38 
Angela Yee-Moon Wang,39 Natasha Wiebe,1 Chih-Wei Yang,40,41 Alexander Zemchenkov,42,43 
Ming-hui Zhao,44,45,46,47 Kitty J Jager,48 Fergus Caskey,49,50 Vlado Perkovic,51 Kailash K Jindal,1 
Ikechi G Okpechi,52,53 Marcello Tonelli,54,55 John Feehally,56 David C Harris,57  
David W Johnson58,59,60
ABSTRACT
OBJECTIVE
To determine the global capacity (availability, 
accessibility, quality, and affordability) to 
deliver kidney replacement therapy (dialysis 
and transplantation) and conservative kidney 
management.
DESIGN
International cross sectional survey.
SETTING
International Society of Nephrology (ISN) survey of 
182 countries from July to September 2018.
PARTICIPANTS
Key stakeholders identified by ISN’s national and 
regional leaders.
MAIN OUTCOME MEASURES
Markers of national capacity to deliver core 
components of kidney replacement therapy and 
conservative kidney management.
RESULTS
Responses were received from 160 (87.9%) of 182 
countries, comprising 97.8% (7338.5 million of 
7501.3 million) of the world’s population. A wide 
variation was found in capacity and structures 
for kidney replacement therapy and conservative 
kidney management—namely, funding mechanisms, 
health workforce, service delivery, and available 
technologies. Information on the prevalence of treated 
end stage kidney disease was available in 91 (42%) 
of 218 countries worldwide. Estimates varied more 
than 800-fold from 4 to 3392 per million population. 
Rwanda was the only low income country to report 
data on the prevalence of treated disease; 5 (<10%) 
of 53 African countries reported these data. Of 159 
countries, 102 (64%) provided public funding for 
kidney replacement therapy. Sixty eight (43%) of 159 
countries charged no fees at the point of care delivery 
and 34 (21%) made some charge. Haemodialysis was 
reported as available in 156 (100%) of 156 countries, 
peritoneal dialysis in 119 (76%) of 156 countries, and 
kidney transplantation in 114 (74%) of 155 countries. 
Dialysis and kidney transplantation were available to 
more than 50% of patients in only 108 (70%) and 45 
(29%) of 154 countries that offered these services, 
respectively. Conservative kidney management was 
available in 124 (81%) of 154 countries. Worldwide, 
the median number of nephrologists was 9.96 per 
million population, which varied with income level.
CONCLUSIONS
These comprehensive data show the capacity of 
countries (including low income countries) to provide 
optimal care for patients with end stage kidney 
disease. They demonstrate substantial variability 
in the burden of such disease and capacity for 
kidney replacement therapy and conservative kidney 
management, which have implications for policy.
Introduction
When chronic kidney disease progresses to the end 
stage, kidney replacement therapy (dialysis or kidney 
transplantation) or conservative kidney management 
(planned, holistic, patient centred care for those with 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Over the past decade, understanding of the global epidemiology and economics 
of kidney disease has improved substantially
More data are available on the burden of acute kidney injury, chronic kidney 
disease, and end stage kidney disease, particularly in low and middle income 
countries
Despite their considerable impact on population health, acute kidney injury and 
chronic kidney disease are generally not included in international, regional, or 
national strategies for chronic disease control
WHAT THIS STUDY ADDS
This study provides a synopsis of the preparedness and capacity of health 
systems worldwide to meet the challenges of end stage kidney disease and 
associated health and economic impacts
It also gives a snapshot of the current capacity to deliver care for end stage 
kidney disease globally, by geographical region and income group, providing 
evidence to guide policy and practice, and enabling monitoring of progress
There is substantial variability in the burden of end stage kidney disease and 
capacity for kidney replacement therapy and conservative kidney management, 
which have implications for policy
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stage 5 chronic kidney disease) is required.1-4 Extensive 
study has been made of the costs and consequences of 
kidney disease—from acute kidney injury to chronic 
kidney disease to end stage kidney disease.5-7 Global 
variations in the burden of kidney disease, related 
care practices, and their determinants have been 
well documented.5 7-15 Consistent and comparable 
data describing the global capacity to deliver kidney 
replacement therapy and conservative kidney manage-
ment have not been reported previously.
The International Society of Nephrology (ISN) led the 
Global Kidney Health Atlas project to define the global 
capacity for kidney care through a multinational, cross 
sectional survey.16 The first iteration of the project in 
2017 explored global international and intranational 
variability in the capacity for kidney care delivery, 
as defined by the World Health Organization. The 
2017 Atlas showed significant inter-regional and 
intraregional variability in global kidney care, with 
appreciable gaps in universal health coverage.16 One 
of the limitations then shown was the lack of detail 
on important elements of care, such as accessibility, 
affordability, and quality of end stage kidney disease 
care.17
This second Global Kidney Health Atlas survey 
aimed at extending the findings of the first and defining 
the global capacity to deliver care for end stage kidney 
disease. Specifically, it includes metrics of availability, 
accessibility, quality, and affordability of services. The 
survey assesses the ability of nations to meet the needs 
of populations for integrated care, including access to 
kidney replacement therapy and conservative kidney 
management. It complements existing data on the 
global burden of end stage kidney disease and is a 
useful tool for policy makers, allowing assessment of, 
and comparison with, countries and regions which are 
dealing with the problem, especially in low and middle 
income countries.
Methods
This iteration of the Global Kidney Health Atlas is 
the product of collaborative efforts with regional 
and national project leaders. Detailed methods are 
published elsewhere.16 18 In brief, two approaches were 
used. Firstly, a systematic review of literature and other 
data sources was carried out to calculate estimates 
of the burden of kidney replacement therapy. This 
burden was defined as the incidence and prevalence of 
end stage kidney disease (overall), and the treatments 
used (that is, haemodialysis, peritoneal dialysis, and 
kidney transplantation). A previously published 
framework was adapted and expanded.19 Data were 
extracted from key reports, including annual reports 
of end stage kidney disease, kidney registries, and 
databases such as the global observatory on donation 
and transplantation.20 In places where no data exist 
in major kidney registries (eg, United States Renal 
Data System, European Renal Association-European 
Dialysis and Transplant Association, and Australian 
and New Zealand Dialysis and Transplant Register), 
additional published and grey literature was searched. 
Secondly, a key opinion leader survey was carried 
out. Three leaders from each country (a nephrology 
society leader, a leader of a patient representative 
organisation, and a policy maker) submitted details on 
national kidney care practices, with a specific focus on 
kidney replacement therapy and conservative kidney 
management. We sought assistance from international 
contacts, collaborators, ISN leaders, and regional 
board members to facilitate both approaches during 
the development of the Global Kidney Health Atlas. 
Project leaders, regionally and nationally, ensured 
that local nephrology association leaders, patient 
representatives, policy makers, and other opinion 
leaders were included. They also organised and 
followed up the responses from all countries and liaised 
between the steering committee, ISN, and regional 
stakeholders; helped to gain access to additional data 
sources and contacts; identified or served as opinion 
leaders on the project for each specific region; and 
vetted and reviewed regional data, or identified others 
to do so.
Survey administration
The survey was sent electronically to people in 182 
countries with ISN affiliate societies. It was coordinated 
through the society’s 10 regional boards—namely, 
Africa, central and eastern Europe, Latin America, 
the Middle East, North America, north and east Asia, 
Oceania and South East Asia, newly independent 
states and Russia, south Asia, and western Europe 
(eFig 1). 
The project was approved by the University of 
Alberta research ethics committee (protocol number: 
PRO00063121). All participants provided informed 
consent. A non-probability, purposive sampling 
approach was used to identify potential survey 
respondents. Specifically, national and regional 
nephrology leaders identified key stakeholders through 
the ISN. These included representatives of national 
nephrology societies, policy makers (comprising those 
directly responsible for the organisation of kidney care 
and those with more general responsibilities), patient 
organisations, foundations, and other advocacy 
groups. Key stakeholders were sent an invitation 
to participate. This included a link to the survey’s 
online portal (an electronic questionnaire via REDCap 
Cloud, https://www.redcapcloud.com). The survey 
was conducted from July to September 2018. During 
this period, regional and national leaders of the ISN 
carried out intensive follow-up by email and telephone 
to ensure complete and timely responses.
Development and validation of the survey 
instrument
The design of the survey questionnaire has been 
described previously.16 18 The questionnaire was 
further developed through a series of reviews with 
the executive committee of the ISN and regional 
leadership. It was peer reviewed for content validity 
and comprehensiveness before being tested with the 
10 regional boards of the ISN to identify any logistical 
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and feasibility problems (eg, need for translation). The 
format and content were finalised based on feedback, 
and the original English language survey questionnaire 
(eAppendix 1) was translated into French and Spanish.
The questionnaire was designed in five modules that 
assessed the national and regional profiles for capacity 
and response to end stage kidney disease. These 
corresponded to each of the six building blocks of 
health systems towards universal health coverage.18 21 
The questionnaire was accompanied by information 
about the Global Kidney Health Atlas, detailed 
instructions for completion, and a glossary of the key 
terms used in the survey.
Data handling and reporting
Responses to the French and Spanish surveys were 
first converted to English by certified translators. Data 
from all individual questionnaires were subsequently 
extracted to Microsoft Excel, cleaned, merged, and 
then combined into a single file to create the global 
database for analysis using Stata 15 software (Stata 
Corporation, 2017).
Responses between respondents from the same 
country were concordant in 112 (70%) of 160 cases. 
Regional leaders of the ISN were asked to ensure that 
collated data were consistent with their understanding 
and were of high quality. Each regional board clari-
fied any ambiguities or inconsistencies. Any major 
inconsistencies remaining after the reviews were 
dealt with systematically during follow-up with the 
survey stakeholders. Findings were further validated 
nationally and regionally by triangulating with 
published literature and grey sources of information 
(eg, government reports and other sources provided by 
the survey respondents).
Data analysis and definition of variables
We used Stata 15 software (Stata, College Station, 
TX) to analyse the data.22-24 Using country as the 
unit of analysis, we synthesised data from multiple 
respondents into a single response for each country by 
contacting regional board representatives to deal with 
data discrepancies. We used a descriptive statistical 
approach to summarise responses to key questionnaire 
domains, and reported counts and percentages. We 
then stratified the results by ISN region and by World 
Bank income group.
We defined the components of kidney replacement 
therapy (dialysis and transplantation) and elements 
of care delivery based on established frameworks.25 
Conservative kidney management was defined and 
analysed based on the Kidney Disease Improving 
Global Outcomes’ (KDIGO) conventions and metrics.4 
Conservative kidney management was defined as 
planned, holistic, patient centred care for patients 
with chronic kidney disease stage 5. It includes 
interventions to delay progression of the disease and 
minimise complications but focuses predominantly on 
management of symptoms and psychological, social, 
cultural, and spiritual support. It does not include 
dialysis.
We defined the key standards of availability, 
accessibility, quality, and affordability based on 
standard metrics.26 Availability was classified as 
“generally available” (in ≥50% centres, hospitals, or 
clinics) or “generally not available” (in <50%). We 
defined accessibility as the proportion of patients 
able to access a given service (eg, dialysis). Quality 
was defined as the proportion of centres that routinely 
measured a given indicator (eg, blood pressure) to 
assess the quality of the service provided. We defined 
affordability as the proportion of the treatment cost 
paid for directly by the patient. Patient reported 
outcome measures were defined as health outcomes 
reported directly by the patient without interpretation 
of their response by others.27 To increase the clarity in 
the survey, we provided examples, including fatigue, 
quality of life, satisfaction, and pain.
We examined the results with an emphasis on 
identifying key gaps in, and challenges to, the delivery 
of kidney replacement therapy and conservative 
kidney management according to the Guidelines for 
Accurate and Transparent Health Estimates Reporting 
(GATHER) statement.24 We followed the Checklist for 
Reporting Results of Internet E-Surveys (CHERRIES)28 
to describe survey development and administration, 
analysis, and reporting (eAppendix 2). Respondents 
were asked to report the number of centres in their 
countries providing kidney replacement services 
(haemodialysis, peritoneal dialysis, and kidney 
transplantation). The concentration overall, by World 
Bank income group and country, was then computed 
by dividing the total number of centres by the overall 
population in millions. Population estimates were 
obtained from the Central Intelligence Agency World 
Factbook midyear 2018. A similar approach was 
used to measure the density of nephrologists and 
nephrology trainees. This is a widely used approach to 
report numbers and distribution of health services and 
resources relative to the population size.21
Patient and public involvement
Patient care organisations (kidney foundations, 
patients’ associations) were involved in the develop-
ment of the survey instrument. The following 
organisations were involved in the survey, and 
their representatives were also selected to respond 
to the survey: International Federation of Kidney 
Foundations, European Kidney Patients’ Federation 
(an umbrella organisation for national kidney patients’ 
associations in Europe), Kidney Foundation of Canada, 
US National Kidney Foundation, and Kidney Health 
Australia. The knowledge dissemination plan will 
involve these consumer organisations. The target end 
users of this research are these consumer organisations, 
policy makers, healthcare providers responsible 
for delivering kidney care, non-profit or advocacy 
organisations, and the public. The design of the project 
was led by nephrologists and the ISN. Individual 
patient data were not used in this study; it was rather a 
survey of healthcare structure and delivery and was not 
based on patient data. Further, there was considerable 
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involvement of policy makers (nephrology society 
leaders and kidney care administrators). We plan 
to disseminate this work widely through the media, 
government groups (ministries of health), and to other 
international stakeholder organisations such as the 
United Nations, WHO, and the World Bank through 
a variety of approaches (eAppendix 3). The report 
is publicly available on the ISN’s website (https://
www2.theisn.org/GKHA) and has received coverage 
from news media (https://www.theisn.org/images/
GKHA_media_coverage.pdf). Additionally, the ISN’s 
regional board members receive the report directly 
so that they can disseminate it to their country focal 
leads and ministers of health. Each country is given a 
country score card, which displays their country level 
data for all key indicators, allowing leaders to identify 
where their country stands relative to the ISN’s region 
and income group. A number of substudy analyses will 
be published in peer reviewed journals. An interactive 
data repository will be created to make the Global 
Kidney Health Atlas data and score cards publicly 
available across countries.
Results
Response rate
Responses were received from 160 (87.9%) of 182 
countries, comprising 97.8% (7338.5 million of 7501.3 
million) of the world’s population (table 1, eFig 2). The 
individual response rate was 68.9% (that is, 317/460 
individuals) and the median number of respondents 
from each country was 3 (interquartile range 2-4; eTable 
1). Results showed statistically significant variability 
among countries in the distribution of capacity for 
kidney replacement therapy and conservative kidney 
management. Important gaps were seen in services 
(including drug treatment, funding, and registries), 
advocacy structures, and workforce (eAppendix 4).
Country readiness, capacity, and response to end 
stage kidney disease
Disease burden: regional and country level 
distribution
Information on the prevalence of treated end stage 
kidney disease was available in 91 (42%) of 218 
countries (fig 1), of which most were high or upper 
middle income countries. Only one low income 
country (Rwanda) and five (9%) of 53 African countries 
provided data on the prevalence of treated end stage 
kidney disease (fig 1). The median prevalence of 
kidney replacement therapy globally was 759 per 
million population (pmp), varying from 4 pmp in 
Rwanda to 3392 pmp in Taiwan (fig 1). Similarly, data 
on the incidence of treated end stage kidney disease 
were available in 79 (36%) of 218 countries (fig 2). No 
low income country and only four (<10%) of 53 African 
countries reported incidence data (fig 2). The median 
rate of treated end stage kidney disease worldwide 
was 144 pmp, ranging from 20 pmp in Paraguay to 
493 pmp in Taiwan (fig 2). Data on individual kidney 
replacement therapy components—chronic dialysis 
(haemodialysis and peritoneal dialysis) and kidney 
transplantation (deceased and living donors)—are 
shown in eFigures 3-12. Information on pre-emptive 
kidney transplantation was available in only 20 (9%) 
of 218 countries. The median rate of pre-emptive 
kidney transplantation operations worldwide was 5.2 
pmp, ranging from 0.3 pmp in Bosnia and Herzegovina 
to 12.4 pmp in Norway (fig 3).
Capacity for provision of kidney replacement therapy
The capacity to deliver chronic dialysis and kidney 
transplantation services varied around the globe 
(eFigs 3-12). Among the 156 countries with chronic 
haemodialysis services, the median number of 
haemodialysis centres was 4.5 pmp (eFig 13). Among 
the 119 countries with chronic peritoneal dialysis 
services, 117 had peritoneal dialysis centres; the global 
median was 1.3 centres pmp (eFig 14). Among the 114 
countries with kidney transplantation services, 113 
had transplantation centres; the global median was 
0.4 centres pmp (eFig 15). Among the countries with 
kidney transplantation services, the sources of donated 
kidneys varied. Eighty two (72%) of 114 kidneys were 
obtained from both deceased and living donors, and 
only 32 (28%) were obtained from living donors. Of 
the 113 countries offering kidney transplantation, 70 
(62%) had national waiting lists, 22 (19%) had only 
regional waiting lists, and 21 (19%) had no waiting list 
(eTable 2).
The availability of kidney replacement does not 
yield much insight into access to treatment. Therefore, 
we also assessed the proportion of countries in 
which more than 50% of medically suitable patients 
reportedly received kidney replacement therapy 
(eTable 3). At least half of such patients could access 
dialysis in 108 (70%) of 154 countries with the service 
available. Treatment with peritoneal dialysis first could 
be started in at least half of suitable patients in five 
(3%) of 154 responding countries, but in fewer than 
a quarter of patients in 96 (62%) countries. Access to 
kidney transplantation was possible for most patients 
(≥50%) in 45 (29%) of 154 responding countries, but 
to only a quarter of patients in 56 (36%) countries 
(eTable 3).
Access to kidney replacement therapy was 
associated with country income—for example, only 
one low income country could offer it to more than 
50% of medically suitable patients. Similarly, neither 
peritoneal dialysis as the initial dialysis modality nor 
kidney transplantation was available for any patients 
in 18 (82%) and 17 (77%) of 22 low income countries, 
respectively. Haemodialysis at home was available 
for only 20 (13%) of 154 countries—all high income 
countries. Most of these were in western Europe 
(n=13), and the rest were in Latin America (n=1), the 
Middle East (n=1), North America (n=2), and Oceania 
and South East Asia (n=3).
Capacity for conservative kidney management 
provision
Conservative kidney management, as defined by 
KDIGO, was available in 124 (81%) of 154 countries. 
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In 66 (43%), choice was restricted (limited by capacity 
to provide kidney replacement therapy) owing to lack 
of resources. In 77 (50%) countries, medically advised 
kidney management (conservative care based on a 
patient’s choice or medical decision that is not limited 
by capacity to provide kidney replacement therapy) 
was available. 
All countries in north, east, and south Asia, and most 
countries in eastern and central Europe (95%, 18/19), 
Oceania and South East Asia (93%, 14/15), western 
Europe (90%, 18/20), the Middle East (82%, 9/11), 
and Africa (80%, 33/41), offered conservative kidney 
management (eTable 4). In contrast, this was offered 
by fewer than half of the countries in Latin America 
(44%, 8/18), and just over half of the countries in 
newly independent states and Russia (57%, 4/7) and 
North America (67%, 6/9; eTable 4). The availability 
of conservative kidney management did not appear 
to be associated with income level: it was provided by 
84% (47/56) of high, 80% (33/41) of upper middle, 
74% (26/35) of lower middle, and 82% (18/22) of 
low income countries (eTable 4). Medically advised 
conservative kidney management, however, increased 
with country income (eTable 4). Moreover, 57 (37%) of 
154 countries with conservative kidney management 
adopted a multidisciplinary team approach to care 
Table 1 | Survey response: countries and population
Category
Countries with  
WB income  
classification
Countries  
receiving survey Countries completing survey
No
Total  
population 
(millions) No
Total  
population 
(millions) No (%)*
Total  
population 
(millions)
Countries 
receiving survey† 
(population %)
Countries with WB 
income classification‡ 
(population %)
Overall 218 7501.3 182 7441.5 160 (87.9) 7338.5 98.6 97.8
ISN region
 Africa 54 1263.7 46 1246.4 42 (91.3) 1213.2 97.3 96.0
  Eastern and central 
Europe
21 215.2 20 209.8 19 (95.0) 209.2
99.7 97.2
  Latin America and 
Caribbean
31 631.4 28 630.9 18 (64.3) 592.4
93.9 93.8
 Middle East 13 243.7 13 243.7 11 (84.6) 213.6 87.6 87.6
 NIS and Russia 10 276.8 10 276.8 10 (100.0) 276.8 100.0 100.0
 North America 14 370.5 13 370.4 10 (76.9) 370.0 99.87 99.86
 North and east Asia 8 1622.1 7 1596.7 7 (100.0) 1596.7 100.0 98.4
 OSEA 30 691.6 16 681.4 15 (93.8) 681.3 99.99 98.5
 South Asia 8 1752.5 7 1752.2 7 (100.0) 1752.2 100.0 99.98
 Western Europe 29 433.7 22 433.2 21 (95.5) 433.1 99.99 99.87
World Bank group
 Low income 30 655.9 26 617.7 23 (88.5) 585.3 94.8 89.2
 Lower middle income 50 2997.8 42 2986.1 38 (90.5) 2941.3 98.5 98.1
 Upper middle income 58 2601.6 48 2592.9 41 (85.4) 2569.3 99.1 98.8
 High income 80 1246.0 66 1244.7 58 (87.9) 1242.5 99.8 99.7
ISN=International Society of Nephrology; NIS=newly independent states; OSEA=Oceania and South East Asia; WB=World Bank
*Percentage calculated as total number of countries that completed the survey/total number of countries that received the survey in the category.
†Proportion calculated as total population of countries that completed the survey/total population of countries that received the survey in the category.
‡Proportion calculated as total population of countries that completed the survey/total population of all countries with a WB income classification.
>1048.0 pmp
759.1-1048.0 pmp
433.0-759.0 pmp
<433.0 pmp 
Data not reported 
Fig 1 | Global prevalence of treated end stage kidney disease, based on individual country data. pmp=per million 
population
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and 40 (26%) used shared decision making tools (eg, 
practice guidelines for providers and patient decision 
aids). Systematic active recognition and management 
of symptoms associated with advanced kidney failure 
were generally available in 80 (52%) of 154 countries. 
Psychological, cultural, and spiritual support were 
provided to people receiving conservative kidney 
management in only 45 (29%) countries (eTable 4).
Health system financing for kidney replacement 
therapy
Overall, 102 (64%) of 159 countries provided public 
funding for kidney replacement therapy. No fees were 
charged at point of delivery by 68 (43%) countries, 
and some fees were charged by 34 (21%; table 2). 
Kidney replacement therapy was funded through a 
mix of public and private systems in 34 (21%) of 159 
countries and through multiple systems (governments, 
non-governmental organisations, and communities) 
in 10 (6%) countries (table 2). Public funding (with or 
without fees at the point of delivery) was less common 
in low income countries (table 2). Coverage for surgical 
services for kidney replacement therapy, including 
fistula, graft, and catheter procedures for haemodialysis, 
catheter insertion for peritoneal dialysis, and kidney 
transplantation, varied worldwide. For instance, over 
half of all countries provided public funding for surgery 
to create vascular access for haemodialysis: 92 (58%) of 
159 covered central venous catheter insertion, and 86 
(54%) covered fistula or graft creation (eTable 5).
Patient copayments (that is, the proportion of the 
treatment cost, including drugs, paid for directly out 
of pocket) for kidney replacement therapy varied 
around the globe (eTable 6). Among the 154 countries 
with haemodialysis available, 41 (27%) had no 
patient copayment, whereas in 23 (15%) countries, 
patients paid more than 75% of the haemodialysis 
cost. In 35 (23%) responding countries, patients 
>200.2 pmp
144.1-200.2 pmp
103.1-144.0 pmp
<103.1 pmp 
Data not reported 
Fig 2 | Global incidence of treated end stage kidney disease, based on individual country data. pmp=per million 
population
>6.9 pmp
5.2-6.9 pmp
1.5-5.1 pmp
<1.5 pmp 
Data not reported 
Fig 3 | Global incidence of pre-emptive kidney transplantation (that is, receiving a kidney transplant before the need to 
start dialysis), based on individual country data. pmp=per million population
 o
n
 29 Novem
ber 2019 at University of Bristol Library. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l5873 on 31 October 2019. Downloaded from 
RESEARCH
the bmj | BMJ 2019;367:l5873 | doi: 10.1136/bmj.l5873 7
had no copayment for peritoneal dialysis, but in 16 
(10%) countries, patients paid more than 75% of the 
cost. In 113 countries where kidney transplantation 
services were available, 35 (31%) had no patient 
copayment, but 15 (13%) had patients paying more 
than 75% of kidney transplantation costs (eTable 6). 
Patient copayment for dialysis was the highest in low 
income countries, where more than 75% of the cost 
for haemodialysis and peritoneal dialysis was out of 
pocket in eight (36%) and four (18%) of 22 countries, 
respectively. Copayment for kidney transplantation 
was the highest in lower middle income countries, 
with patients covering more than 75% of the cost in 
seven (29%) of 24 countries (eTable 6).
Funding for drugs used in end stage kidney disease 
care
Among the 153 countries that offered dialysis, 94 
(61%) provided government funding for patients’ 
drugs; 62 countries charged patients no fees and 32 
charged some fees at the point of delivery (table 3). 
In contrast, 15 (10%) of 153 countries funded drugs 
for patients undergoing dialysis exclusively through 
private sources (table 3). Among the 113 countries 
that offered kidney transplantation, 84 (74%) covered 
drug treatment costs through government funding; 
64 countries charged patients no fees and 20 charged 
some fees at the point of delivery (table 4). In contrast, 
six (5%) of 113 funded drugs for transplant patients 
exclusively through private sources (table 4).
Availability of services for end stage kidney disease 
care
Availability of services for end stage kidney disease 
care (that is, diagnostic tests and treatment for blood 
pressure, anaemia, renal bone disease, electrolytes, 
and acid base disorders) varied globally. Availability 
was limited greatly among low income countries 
(eTables 7-9). Most countries had the capacity to 
measure serum haemoglobin, provide oral iron 
supplementation, and monitor iron variables (eTable 
7). Fewer countries had the capacity to administer 
non-calcium-based phosphate binders (47%, 73/155) 
and cinacalcet (37%, 58/155) (eTable 8). The capacity 
to manage electrolyte disorders and chronic metabolic 
acidosis was high in most countries (eTable 9).
Workforce for delivery of end stage kidney disease 
care 
Respondents were asked to estimate the number of 
nephrologists and nephrology trainees, as defined 
by regulatory authorities, and provide details of their 
role. Additionally, they were asked whether there 
was a shortage (yes/no) of the workforce required for 
delivery of end stage kidney disease care. Overall, 
nephrologists were primarily responsible for care 
for end stage kidney disease in 144 (92%) of 157 
countries. Care was also provided by primary care 
physicians jointly with nephrologists in 34 (22%) 
of 157 countries. Other providers were primarily 
responsible for end stage kidney disease care in 
three (2%) of 157 countries. Worldwide, the median 
number of nephrologists was 9.96 pmp (eFig 16). 
The number of nephrologists by country increased 
with income level, with low income countries having 
the lowest prevalence (0.4 pmp), followed by lower 
middle (5.0 pmp), upper middle (13.5 pmp), and high 
(26.5 pmp) income countries (eFig 16). The median 
number of nephrology trainees was 1.4 pmp (eFig 17), 
with considerable variation across countries (eFig 
17). All countries reported shortages of providers 
essential for end stage kidney disease care (eFig 
Table 2 | Funding for provision of services for chronic kidney replacement therapy. Data are number (%) of countries
Category
No of  
responding 
countries
Public
Mix of 
public and 
private
Private
Multiple 
systems* N/A† Other‡
Free at point 
of delivery
Some fees 
at point of 
delivery
Out of 
pocket
Health  
insurance
Overall 159 68 (43) 34 (21) 34 (21) 7 (4) 1 (1) 10 (6) 1 (1) 4 (3)
ISN region
Africa 42 11 (26) 11 (26) 12 (29) 3 (7) 0 (0) 3 (7) 1 (2) 1 (2)
Eastern and  
central Europe
19 15 (79) 1 (5) 2 (11) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5)
Latin America  
and Caribbean
18 4 (22) 3 (17) 9 (50) 1 (6) 0 (0) 1 (6) 0 (0) 0 (0)
Middle East 11 10 (91) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
NIS and Russia 9 6 (67) 2 (22) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11)
North America 10 2 (20) 0 (0) 7 (70) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
North and east Asia 7 1 (14) 5 (71) 1 (14) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
OSEA 15 4 (27) 5 (33) 2 (13) 1 (7) 0 (0) 3 (20) 0 (0) 0 (0)
South Asia 7 1 (14) 1 (14) 1 (14) 1 (14) 0 (0) 3 (43) 0 (0) 0 (0)
Western Europe 21 14 (67) 5 (24) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 1 (5)
World Bank group
Low income 23 5 (22) 6 (26) 5 (22) 4 (17) 0 (0) 1 (4) 1 (4) 1 (4)
Lower middle income 37 11 (30) 10 (27) 6 (16) 2 (5) 0 (0) 7 (19) 0 (0) 1 (3)
Upper middle income 41 18 (44) 7 (17) 15 (37) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0)
High income 58 34 (59) 11 (19) 8 (14) 1 (2) 1 (2) 1 (2) 0 (0) 2 (3)
ISN=International Society of Nephrology; NIS=newly independent states; OSEA=Oceania and South East Asia.
*Programmes provided by governments, non-governmental organisations, and communities.
†Kidney replacement therapy not available.
‡Other funding mechanisms not included in the survey.
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18). Many countries (70%, 109/156) did not have 
enough nephrologists, interventional radiologists 
for haemodialysis access (66%, 103/156), surgeons 
for peritoneal dialysis access (51%, 79/156), or 
transplant surgeons (65%, 102/156; eFig 18). 
Compared with the previous Global Kidney Health 
Atlas survey, the median number of nephrologists 
worldwide has increased by 0.22 pmp (eAppendix 
5).This improvement corresponds with income level, 
with low income countries reporting the lowest 
increase (0.03 pmp), followed by lower middle 
(0.12 pmp), upper middle (0.53 pmp), and high 
(0.82 pmp) income countries (eAppendix 5).
Global distribution of end stage kidney disease 
registries and reporting on quality indicators of 
kidney replacement therapy
Respondents from 13 countries reported registries 
for acute kidney injury and those from 19 reported 
registries for non-dialysis chronic kidney disease 
(eTable 10). Most countries surveyed had registries for 
dialysis (66%, 101/154) and kidney transplantation 
(57%, 88/154; eTable 10).
Respondents were asked how often their countries 
measured and reported key quality indicators for kidney 
replacement therapy service delivery. Of 144 countries 
with haemodialysis services, 77 (53%) measured 
patient reported outcome measures at least 50% of 
the time (eFig 19). Commonly reported indicators 
included blood pressure, haemoglobin/packed cell 
volume, small solute clearance, bone mineral markers, 
technique, and patient survival (eFig 19). Among the 
112 countries with kidney transplantation services, 65 
(58%) measured patient reported outcome measures 
at least 50% of the time (eFig 20). A large proportion 
of countries reported patient survival (77%, 86/111), 
kidney allograft function (73%, 82/112), and graft 
survival (72%, 80/111; eFig 20).
Leadership and governance
Oversight of end stage kidney disease varied across 
countries and regions. Care was managed by national 
governments in 89 (56%) of 159 countries; hospitals, 
trusts, and organisations in 61 (38%) countries; 
provincial, regional, or state governments in 34 (21%) 
countries; non-governmental organisations in seven 
(4%) countries; and other management structures in 
12 (8%) countries (eTable 11). Advocacy and support 
for end stage kidney disease and kidney replace- 
ment therapy varied across countries and regions 
(eTable 12).
Country variations in paediatric kidney care services
Nearly a quarter (37/157, 24%) of countries reported 
that access to kidney replacement therapy differed 
between children and adults. Variation was highest 
among low income countries (13/23, 57%) followed 
by lower middle (14/36, 39%), upper middle (5/41, 
12%), and high (5/57, 9%) income countries. 
Organisation or delivery of care for end stage kidney 
disease also differed between children and adults in 47 
(30%) of 157 countries. Similarly, variation decreased 
as income level increased. Of 23 low income countries, 
14 (61%) reported differences between children and 
adults, followed by 14 (39%) of 36 lower middle, eight 
(20%) of 41 upper middle, and 11 (19%) of 57 high 
income countries.
Changes in region and country reports from 2017 to 
2019
This survey included 160 countries compared with 125 
in the initial survey,16 and covered over 98% (7338.5 
Table 3 | Funding for drug treatments among patients receiving dialysis across regions. Data are number (%) of 
countries
Category
No of  
responding  
countries
All patients receiving dialysis
Public funding
Mix of public 
and private 
funding
Private funding
Multiple 
systems* Other†
Free at point 
of delivery
Some fees 
at point of 
delivery
Out of 
pocket
Heath  
insurance
Overall 153 62 (41) 32 (21) 35 (23) 15 (10) 2 (1) 5 (3) 2 (1)
ISN region
Africa 40 9 (23) 6 (15) 12 (30) 10 (25) 1 (3) 2 (5) 0 (0)
Eastern and central Europe 19 18 (95) 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Latin America and Caribbean 18 5 (28) 3 (17) 8 (44) 1 (6) 0 (0) 1 (6) 0 (0)
Middle East 11 8 (73) 2 (18) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0)
NIS and Russia 7 3 (43) 2 (29) 1 (14) 0 (0) 0 (0) 0 (0) 1 (14)
North America 9 1 (11) 2 (22) 5 (56) 1 (11) 0 (0) 0 (0) 0 (0)
North and east Asia 7 2 (29) 4 (57) 0 (0) 1 (14) 0 (0) 0 (0) 0 (0)
OSEA 15 5 (33) 3 (20) 4 (27) 1 (7) 0 (0) 2 (13) 0 (0)
South Asia 7 2 (29) 1 (14) 3 (43) 1 (14) 0 (0) 0 (0) 0 (0)
Western Europe 20 9 (45) 8 (40) 1 (5) 0 (0) 1 (5) 0 (0) 1 (5)
World Bank group
Low income 21 4 (19) 2 (10) 5 (24) 10 (48) 0 (0) 0 (0) 0 (0)
Lower middle income 35 8 (23) 7 (20) 13 (37) 3 (9) 1 (3) 3 (9) 0 (0)
Upper middle income 41 22 (54) 5 (12) 11 (27) 1 (2) 0 (0) 1 (2) 1 (2)
High income 56 28 (50) 18 (32) 6 (11) 1 (2) 1 (2) 1 (2) 1 (2)
ISN=International Society of Nephrology; NIS=newly independent states; OSEA=Oceania and South East Asia.
*Programmes provided by governments, non-governmental organisations, and communities.
†Other funding mechanisms not included in the survey.
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million/7501.3 million) of the world population 
(eAppendices 4 and 5). It examined the availability of 
kidney replacement therapy, its accessibility, quality, 
and affordability. Comparison of those countries 
responding to both iterations of the survey (n=113) 
showed that some availability of chronic haemodialysis 
was reported in both surveys. Chronic peritoneal 
dialysis was available in 90 (80%) of 113 countries in 
both surveys. Four countries (Bolivia, Egypt, Fiji, and 
Swaziland) without peritoneal dialysis availability 
previously reported this as available in the current 
survey, whereas four countries (Armenia, Kenya, Syria, 
and Uganda) with previously reported peritoneal 
dialysis available now reported non-availability 
(eAppendices 4 and 5). Kidney transplantation was 
available in 87 (77%) of 113 countries in the previous 
survey compared with 88 (78%) of 113 countries 
in this survey (eAppendices 4 and 5). Registries for 
chronic kidney disease and acute kidney injury existed 
in seven (6%) and six (5%) countries in the previous 
survey, compared with 11 (10%) and seven (6%) 
countries in this survey, respectively (eAppendices 4 
and 5).
All the 47 additional countries in this survey reported 
at least some availability of chronic haemodialysis. 
Chronic peritoneal dialysis and kidney transplantation 
were available in 28 (60%) and 23 (49%) of these 
countries, respectively (eAppendices 4 and 5).
Discussion
The aim of the Global Kidney Health Atlas initiative is to 
document the state of kidney care across six domains 
of the health system worldwide, and to provide a 
score card to evaluate capacity for integrated delivery 
of kidney related healthcare, including dialysis, 
transplantation, and conservative care.21 The first 
assessment in 2017 showed variability in global kidney 
care. Considerable gaps in care were found across all 
domains, particularly in low income and lower middle 
income countries.16 This survey extends these findings 
by providing information on the full spectrum of care 
for end stage kidney disease. It provides information 
also on other services, such as registry and reporting 
of quality measures and the workforce necessary for 
optimal care.
This document describes the results of the 2019 
survey, two years after the first. It aims to assess global 
capacity to deliver the structures and organisation 
for end stage kidney disease care in accordance with 
the key building blocks of a functional health system 
(availability, accessibility, quality, and affordability).
Principal findings of the study
Findings from this survey show that most participating 
countries (64%, 102/159) provided public funding for 
kidney replacement therapy. Fewer than half (48%, 
11/23) of low income countries and just over half (57%, 
21/37) of lower middle income countries provided 
public funding. This greatly reduces access to care in 
countries with fewer resources, resulting in potentially 
preventable death or morbidity. The concentration of 
nephrologists in high income countries was over 60 
times that in low income countries. Most low income 
countries also reported shortages of interventional 
radiologists, surgeons, and transplant coordinators. 
Nearly all countries offered haemodialysis, and 
three quarters offered peritoneal dialysis and trans-
plantation services. Few low income countries, 
however, provided these services. The costs of chronic 
haemodialysis facilities are high. More affordable 
peritoneal dialysis might enable poorer countries to 
improve their capacity to deliver care for end stage 
Table 4 | Funding for drugs among patients living with kidney transplant across regions. Data are number (%) of 
countries
Category
No of  
responding  
countries
All patients with kidney transplant
Public funding Mix of public 
and private 
funding
Private funding
Multiple  
systems*
Free at point  
of delivery
Some fees at point 
of delivery
Out of 
pocket
Heath  
insurance
Overall 113 64 (57) 20 (18) 15 (13) 6 (5) 5 (4) 3 (3)
ISN region 
Africa 14 5 (36) 1 (7) 4 (29) 3 (21) 1 (7) 0 (0)
Eastern and central 
Europe 18 17 (94) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0)
Latin America and 
Caribbean 17 7 (41) 2 (12) 3 (18) 1 (6) 3 (18) 1 (6)
Middle East 11 9 (82) 1 (9) 0 (0) 0 (0) 1 (9) 0 (0)
NIS and Russia 7 5 (71) 0 (0) 0 (0) 1 (14) 0 (0) 1 (14)
North America 5 3 (60) 1 (20) 1 (20) 0 (0) 0 (0) 0 (0)
North and east Asia 7 2 (29) 5 (71) 0 (0) 0 (0) 0 (0) 0 (0)
OSEA 10 5 (50) 2 (20) 3 (30) 0 (0) 0 (0) 0 (0)
South Asia 6 1 (17) 1 (17) 3 (50) 1 (17) 0 (0) 0 (0)
Western Europe 18 10 (56) 6 (33) 1 (6) 0 (0) 0 (0) 1 (6)
World Bank group 
Low income 5 1 (20) 1 (20) 1 (20) 2 (40) 0 (0) 0 (0)
Lower middle income 24 10 (42) 2 (8) 5 (21) 4 (17) 3 (13) 0 (0)
Upper middle income 34 23 (68) 3 (9) 4 (12) 0 (0) 2 (6) 2 (6)
High income 50 30 (60) 14 (28) 5 (10) 0 (0) 0 (0) 1 (2)
ISN=International Society of Nephrology; NIS=newly independent states; OSEA=Oceania and South East Asia.
*Programmes provided by governments, non-governmental organisations, and communities.
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kidney disease. Alternatively, more affordable models 
of care, such as point of care dialysate production (eg, 
the Affordable Dialysis Project),29 simplification of 
technology equipment, and use of community based 
multi-user self care facilities, might help to provide 
more sustainable kidney replacement therapy in 
lower middle income countries. Services to manage 
complications of end stage kidney disease, such as 
anaemia, high blood pressure, electrolyte disorders, 
metabolic acidosis, and renal bone disease, were also 
limited, especially in low and lower middle income 
countries.
Kidney transplantation in suitable patients provides 
the best outcomes at the lowest cost. Development 
of sustainable programmes is often constrained by a 
lack of access to key ancillary services, such as tissue 
typing laboratories and surgical expertise. Partnership 
with regional professional associations, industry, and 
nearby countries willing to share resources could 
increase local capacity.
This survey provides new information on the 
availability of, and capacity for, conservative kidney 
management. The availability of conservative kidney 
management did not appear to be associated with 
income level, primarily because the provision of 
choice restricted conservative kidney management 
was included. The availability of chosen or medically 
advised conservative kidney management increased 
with country income level: 40 (71%) of 56 high income 
countries offered conservative kidney management, 
compared with 21 (51%) of 41 upper middle, 10 
(29%) of 35 lower middle, and six (27%) of 22 low 
income countries. When kidney replacement therapy 
is available, the decision to choose conservative kidney 
management requires shared decision making between 
providers and patients. Factors such as lifestyle, 
values, health outcomes, and quality of life, should 
be considered.4 The expertise and infrastructure 
required to support this important choice will become 
increasingly important as kidney replacement therapy 
becomes more widely available.
Health policy implications
End stage kidney disease is well recognised as a major 
public health concern. Its treatment is expensive 
(consuming 2-3% of the healthcare budget in wealthy 
nations), and a burden to patients, families, and 
the healthcare system.10 The problem is a growing 
one, with the incidence of end stage kidney disease 
rising worldwide, and the fastest growth occurring 
in low and middle income countries.5 Access to 
treatment is limited in these countries. For example, 
an estimated 2.3 to 7.1 million people who required 
kidney replacement, mainly in low and middle income 
countries, are thought to have died because they were 
unable to receive it.5 Access to care for end stage kidney 
disease care is thus critical to reducing global mortality 
from non-communicable diseases. 
Our findings have important implications for 
patients and their families, healthcare professionals, 
and policy makers. As the magnitude of the burden of 
end stage kidney disease and financial consequences 
for the health system become increasingly apparent, 
the need to prioritise prevention becomes critical. This 
need is particularly true for low and middle income 
countries2 30 31 and vulnerable and disadvantaged 
populations in high income regions.30 31 Prevention of 
chronic kidney disease and end stage kidney disease is 
much more cost effective than providing care for end 
stage kidney disease.30 32 However, optimal prevention 
and treatment of kidney disease will not obviate the 
need for kidney replacement.
Our study identified inequities in kidney care delivery 
among children, particularly in low and lower middle 
income countries. The variability in access to care 
among marginalised population groups, particularly 
women and children, should also be dealt with.
Hence, if there were no financial constraints, end 
stage kidney disease care should ideally be available 
as a mix of peritoneal dialysis, haemodialysis, 
transplantation, and conservative kidney management 
(that is, non-dialytic care), and patients should be able 
to choose and move between the different modalities. 
For suitable patients, transplantation provides the 
optimal length and quality of life.33 For a substantial 
proportion of the rest, the best option is conservative 
kidney management because many patients will want 
kidney replacement therapy but do not have immediate 
access to it. Although conservative kidney management 
is an essential component of an integrated end stage 
kidney disease care programme, it should not be seen 
as a low cost alternative to the development of kidney 
replacement therapy programmes in low and middle 
income countries.34 If resource constraints limit the 
availability of kidney replacement therapy, then 
conservative kidney management should be clearly 
identified as choice restricted.
The implications of our findings in relation to the 
activities of other stakeholders (such as the WHO, 
World Bank, and others) already working to close gaps 
in care should also be highlighted.35 36 These include 
the WHO triple billion target aimed at improving access 
to primary healthcare while ensuring sustainable 
financing and financial protection, refining national 
health policies, and developing effective surveillance 
systems.37 Global efforts to achieve the sustainable 
development goals align with the implications of our 
findings. Achieving these goals will enable countries 
to achieve a degree of prosperity so that kidney 
replacement therapy could be provided without a net 
loss due to opportunity cost.35 38
Strengths and weaknesses of the study
Our manuscript has several key strengths. The survey 
was based on a well validated conceptual framework 
for assessing care capacity for other chronic diseases 
and used the WHO health system building blocks. 
Data were reviewed for accuracy by regional and 
national stakeholders with local knowledge of their 
countries and regions. Furthermore, responses were 
collected from several countries covering almost the 
entire global population (98%, 7338.5 million/7501.3 
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million); coverage across regions and income levels 
was also good. To deal with some of the limitations 
of the first survey, we assessed other measurements 
of health system performance. These measurements 
include availability, accessibility, financing, quality 
and monitoring, and regional variability. 
This survey, however, shares some limitations with 
its predecessor. Questionnaire surveys could introduce 
subjectivity (social desirability bias), and depend on 
respondents’ knowledge, expertise, and perceptions. 
The survey questions were assessed for face validity, 
but our findings depend on how correctly respondents 
represented the status of services. Therefore, we 
worked closely with the ISN’s regional boards to select 
respondents with a range of kidney care knowledge 
and expertise. At the same time, we ensured adequate 
regional representation, and corroborated findings 
with regional leaders and secondary data sources. The 
relative dearth in quantity and quality of information 
available from low and middle income countries should 
be acknowledged. The data from these countries 
could depend particularly on regional experts rather 
than national databases, which might have affected 
the interpretation and application of data from those 
regions.
We selected countries with available stakeholders 
to complete the surveys. Only 36 countries were not 
included in this survey, and they mostly lacked kidney 
care services or relied on neighbouring countries 
to provide them. Most of these excluded countries 
were independent territories and small islands. If 
they did not participate owing to limited information 
or resources or political focus on kidney care, their 
exclusion might have resulted in an overestimated 
capacity. These countries, however, comprised a range 
of geographical and economic levels. We speculate 
that their lack of participation was random, and 
probably did not affect the overall estimates. As we 
collected data from countries covering 98% (7338.5 
million/7501.3 million) of the global population, 
the proportion excluded from these 36 countries was 
minimal.
Conclusions
This work provides comprehensive data on the 
capacity of countries (including low income nations) 
to provide optimal care for patients with end stage 
kidney disease. The first iteration of the Global 
Kidney Health Atlas demonstrated significant inter-
regional and intraregional variability in global 
kidney care, with appreciable gaps in the key 
health system building blocks (eg, care structures, 
workforce, financing).16 17 This study provides detail 
on accessibility, affordability, and quality of dialysis, 
transplantation, and conservative care, which were 
not covered by its predecessor. Global variations in 
the burden of kidney disease, related care practices, 
and their determinants have been well documented. 
This study documents consistent and comparable data 
using a formal framework to describe global capacity 
to deliver care to those with kidney failure. The data 
collection involved an international collaboration 
across major stakeholders from 160 countries 
containing 98% (7338.5 million/7501.3 million) of 
the world population. The work provides a policy and 
advocacy tool for promoting access to kidney care 
across the globe. Our findings will help policy makers 
to make more informed decisions about resource 
allocation and prioritisation of services. Our findings 
also affect strategies to reduce the societal burden of 
chronic kidney disease and track national progress 
towards equitable and sustainable care throughout the 
continuum of kidney care.36 39 40
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